RxDoctor Payments Data

Dwain Woode, MD

Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1962626242

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $62,259 of the $77,551 with a category attached, or 80.3%. 31 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 36.1% of the total. Reporting peaked in 2019 at $22,308 and has fallen 94.1% since, to $1,325 in 2025.

$77,551in general payments, 2019–2025

Across 991 payments — averaging $78.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$28K
  • Boehringer Ingelheim$20K
  • Lilly USA, LLC$11K
  • Merck$6K
  • Novo Nordisk$4K
  • Medtronic$3K
  • plus $6K from 25 others

What the payments were for

  • Consulting fees$4881%
  • Speaking & faculty fees$62,25980%
  • Travel & lodging$750%
  • Food & beverage$14,69519%
  • Education$350%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,551 in reported general payments places this provider in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama

Medicare billing

Part B allowed, 2024
$154,030
Medicare patients
304
Services billed
1,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide251$426,851
MounjaroTirzepatide185$272,397
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7140$221,816
JardianceEmpagliflozin160$187,893
Trijardy XrEmpaglifloz/Linaglip/Metformin149$156,600
JanuviaSitagliptin Phosphate127$142,000
Humulin R U-500Insulin Regular, Human47$127,718
RybelsusSemaglutide55$120,275
LyumjevInsulin Lispro-Aabc58$106,069
TradjentaLinagliptin92$99,586
GlyxambiEmpagliflozin/Linagliptin58$86,783
Tresiba Flextouch U-100Insulin Degludec63$72,603
TrulicityDulaglutide32$69,694
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog87$66,490
FarxigaDapagliflozin Propanediol53$65,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Fiasp$3,717$643,119428 claims
Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi$19,805$530,861459 claims
Lilly USA, LLCMounjaro, Lyumjev, Trulicity, Humalog, Insulin Lispro$11,272$526,016491 claims
MerckJanuvia, Janumet, Janumet Xr$6,003$173,996163 claims
AstraZenecaFarxiga$472$65,90253 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$28,024$64,69874 claims
AbbVieSynthroid$1,828$10,85897 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

Other endocrinology, diabetes & metabolism in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →